Engaging Gut-to-Brain Signalling to Treat Alcohol Use Disorder

Area of Science:

• Neuroscience
• Pharmacology
• Gastroenterology

Background:

• Alcohol use disorder (AUD) affects millions, with limited effective medication options.
• Current AUD treatments have variable efficacy and low adoption rates.
• Chronic alcohol use poses significant health and economic burdens.

Purpose of the Study:

• To investigate Nezavist, a novel small molecule, as a potential medication for AUD.
• To explore Nezavist's mechanism of action, particularly its peripheral effects.
• To provide evidence supporting Nezavist's efficacy in reducing alcohol relapse.

Main Methods:

• Studied Nezavist's effects on alcohol consumption in established animal models of alcohol dependence.
• Conducted pharmacokinetic analysis to determine Nezavist's distribution.
• Hypothesized and investigated a gut-brain axis mechanism involving the vagus nerve.

Main Results:

• Nezavist significantly reduced relapse to chronic alcohol consumption in animal models.
• Pharmacokinetic studies confirmed Nezavist does not enter the central nervous system (CNS).
• Evidence suggests Nezavist stimulates vagal afferents from the intestine, potentially reducing brain inflammation and alcohol craving.

Conclusions:

• Nezavist demonstrates potential as a novel therapeutic agent for AUD.
• The drug's efficacy appears mediated by a peripheral gut-brain pathway, not direct CNS action.
• Further research is warranted to confirm Nezavist's mechanism and clinical utility for addiction treatment.